Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Fosfocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL9319921 | 0.87 | MVD (0.41) | MVDMEN1LMNAKMT2A | |
| Fosfocreatine SCHEMBL65424 | 0.87 | MVD (0.41) | MVDMEN1LMNAKMT2A | |
| Fosfocreatine SCHEMBL21381775 | 0.85 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL3026725 | 0.85 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL2635000 | 0.85 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL1640491 | 0.85 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL612833 | 0.85 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL23828690 | 0.84 | MVD (0.39) | MVD | |
| Fosfocreatine SCHEMBL21381730 | 0.84 | MVD (0.39) | MVD | |
| Fosfocreatine SCHEMBL21381695 | 0.84 | MVD (0.39) | MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322383-A1 | NEUROPROTECTIVE DISRUPTION OF KV2.1/SYNTAXIN INTERACTION BY SMALL MOLECULES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-21 | — | — | US | disclosed |
| US-20200240980-A1 | METHOD FOR DELAYED RECTIFIER CURRENT ENHANCEMENT, CHARACTERIZATION, AND ANALYSIS IN HUMAN INDUCED PLURIPOTENT STEM CELLS | UNIV NEW YORK STATE RES FOUND (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2020028515-A1 | NEUROPROTECTIVE DISRUPTION OF KV2.1/SYNTAXIN INTERACTION BY SMALL MOLECULES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2019075353-A1 | METHOD FOR DELAYED RECTIFIER CURRENT ENHANCEMENT, CHARACTERIZATION, AND ANALYSIS IN HUMAN INDUCED PLURIPOTENT STEM CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-04-18 | — | — | WO | disclosed |
| US-8771741-B2 | In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140154325-A1 | IN VIVO PHOTODYNAMIC THERAPY OF CANCER VIA A NEAR INFRARED AGENT ENCAPSULATED IN CALCIUM PHOSPHATE NANOPARTICLES | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-06-05 | — | — | US | disclosed |
| CN-102399280-A | Sea anemone cardiotonic peptide and extraction method and application thereof | UNIV ZHEJIANG OCEAN | 2012-04-04 | — | — | CN | disclosed |
| US-7816074-B2 | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100247436-A1 | In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles | THE PENN STATE RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010085651-A1 | IN VIVO PHOTODYNAMIC THERAPY OF CANCER VIA A NEAR INFRARED AGENT ENCAPSULATED IN CALCIUM PHOSPHATE NANOPARTICLES | THE PENN STATE RESEARCH FOUNDATION (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090269795-A1 | Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2009-10-29 | — | — | US | disclosed |
| US-20070081943-A1 | Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism | SMITH SHERYL | 2007-04-12 | — | — | US | disclosed |
| WO-2005011612-A2 | ALPHA 4 BETA 2 DELTA GABA-A RECEPTORS AS A STRATEGY FOR PMS AND ALCOHOLISM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-02-10 | — | — | WO | disclosed |
| US-4954642-A | INOTROPIC, HYPOTENSIVE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322383-A1 | NEUROPROTECTIVE DISRUPTION OF KV2.1/SYNTAXIN INTERACTION BY SMALL MOLECULES | STXBP1, KCNN2, KCNN1 | MVD 2726/4885MEN1 2241/4885LMNA 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.